Cardiovascular Safety and State-of-the-art Development Issues: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity

17 - 18 April 2012, Washington, DC, United States

Introduction

Join Industry Experts and Regulators to Improve Your Safety Analysis During Drug Development, Analyze and Mitigate Potential Risks, and Explore New Solutions and Approaches to Developing Safe and Effective Medications, including those to treat Type 2 Diabetes Mellitus.

Event Code:
12009